Research graph
References from Comparative analysis of low- and high-dose apheresis platelets in platelet-refractory patients with hematologic malignancies. Local targets link to admitted publications; unresolved targets remain external evidence.
Platelet transfusions
10.1016/s0140-6736(07)61198-2 · 2007 · External reference
The appropriateness of platelet transfusions in hematological patients and the potential for improvement
10.1016/j.tracli.2022.11.007 · 2023 · External reference
Platelet transfusion: and update on challenges and outcomes
10.2147/jbm.s234374 · 2020 · External reference
Diagnosis and treatment of immunological platelet refractoriness by histocompatibility
10.1016/j.humimm.2020.02.005 · 2020 · External reference
Frequency and causes of refractoriness in multiply transfused patients
10.1007/s002770050280 · 1997 · External reference
Current status of and global trends in platelet transfusion refractoriness from 2004 to 2021: a bibliometric analysis
2022 · External reference
Prevalence of risk factors forplatelet transfusion refractoriness in multitransfused patients with hematologic malignancies attertiary care center in North India
10.4103/0973-6247.150953 · 2015 · External reference
Unresolved reference
2003 · External reference
Efficacy of cross-match compatible platelets in multi transfused haemato-oncology patients refractory to platelet transfusion
10.1016/j.transci.2019.09.010 · 2019 · External reference
Platelet compatibility and platelet antibodies detection: a step towards resolving dilemma in management of platelet refractoriness in oncology patients
10.4103/gjtm.gjtm_51_19 · 2019 · External reference
Platelet alloimmunization in multitransfused patients with haemato-oncologicaldisorders
2005 · External reference
Comparison of efficacy of low and high-dose prophylactic platelet transfusion therapy in thrombocytopenic haemato-oncology patients
10.1016/j.transci.2019.06.033 · 2020 · External reference
Dose of prophylactic platelet transfusions and prevention of hemorrhage
10.1056/nejmoa0904084 · 2010 · External reference
A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia
10.1182/blood-2008-09-178236 · 2009 · External reference
Frequency and causes of refractoriness in multiply transfused patients
10.1007/s002770050280 · ExternalCitation · doi-reference
Diagnosis and treatment of immunological platelet refractoriness by histocompatibility
10.1016/j.humimm.2020.02.005 · ExternalCitation · doi-reference
The appropriateness of platelet transfusions in hematological patients and the potential for improvement
10.1016/j.tracli.2022.11.007 · ExternalCitation · doi-reference
Comparison of efficacy of low and high-dose prophylactic platelet transfusion therapy in thrombocytopenic haemato-oncology patients
10.1016/j.transci.2019.06.033 · ExternalCitation · doi-reference
Efficacy of cross-match compatible platelets in multi transfused haemato-oncology patients refractory to platelet transfusion
10.1016/j.transci.2019.09.010 · ExternalCitation · doi-reference
Platelet transfusions
10.1016/s0140-6736(07)61198-2 · ExternalCitation · doi-reference
Dose of prophylactic platelet transfusions and prevention of hemorrhage
10.1056/nejmoa0904084 · ExternalCitation · doi-reference
A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia
10.1182/blood-2008-09-178236 · ExternalCitation · doi-reference
Platelet transfusion: and update on challenges and outcomes
10.2147/jbm.s234374 · ExternalCitation · doi-reference
Prevalence of risk factors forplatelet transfusion refractoriness in multitransfused patients with hematologic malignancies attertiary care center in North India
10.4103/0973-6247.150953 · ExternalCitation · doi-reference
Platelet compatibility and platelet antibodies detection: a step towards resolving dilemma in management of platelet refractoriness in oncology patients
10.4103/gjtm.gjtm_51_19 · ExternalCitation · doi-reference
